Related Experiment Video
Updated: Jun 13, 2026

09:30
Assessment of Long-term Depression Induction in Adult Cerebellar Slices
Published on: October 16, 2019
Pregabalin Depresses Cerebellar Parallel Fiber-Purkinje Cell Synaptic Transmission by Modulating Glun2a-Containing
Mei-Rui Li1,2, Xu-Dong Zhang1,2, Li Chen1,2
1Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji 133002, China.
International Journal of Molecular Sciences
|June 12, 2026
Summary
Pregabalin (PGB) inhibits cerebellar synaptic transmission by reducing glutamate release via a presynaptic α2δ-1-NMDAR/PKA pathway. This finding clarifies PGB
Area of Science:
- Neuroscience
- Pharmacology
- Cellular Biology
Background:
- Pregabalin (PGB) targets α2δ subunits of voltage-gated calcium channels, modulating brain synaptic transmission.
- The specific impact of PGB on cerebellar parallel fiber-Purkinje cell (PF-PC) synaptic transmission is not well understood.
Purpose of the Study:
- To investigate the effects of PGB on PF-PC synaptic transmission in the mouse cerebellar cortex.
- To elucidate the underlying molecular mechanisms, including the roles of N-methyl-D-aspartate receptors (NMDARs) and protein kinase A (PKA).
Main Methods:
- Whole-cell patch-clamp recording to measure synaptic currents.
- Glutamate fluorescence imaging to assess neurotransmitter release.
- Immunohistochemistry, co-immunoprecipitation, and Western blotting to analyze protein interactions and signaling pathways.
- Pharmacological approaches using receptor blockers and kinase inhibitors.
Main Results:
- PGB concentration-dependently inhibited PF-PC excitatory postsynaptic currents (EPSCs) and increased the paired-pulse ratio, indicating reduced presynaptic release.
- PGB reduced evoked glutamate release and the frequency of miniature EPSCs (mEPSCs) without altering their amplitude.
- These effects were abolished by extracellular blockade of GluN2A-containing NMDARs or disruption of α2δ-1-NMDAR complexes, and by extracellular PKA inhibition.
- PGB increased PKA phosphorylation in the cerebellar molecular layer, and α2δ-1 and GluN2A subunits were found to be co-localized and interacting.
Conclusions:
- PGB depresses glutamate release from parallel-fiber terminals in the mouse cerebellum.
- This occurs through a presynaptic mechanism involving α2δ-1-coupled GluN2A-containing NMDARs and the PKA signaling pathway.
- PGB attenuates PF-PC synaptic transmission via this novel presynaptic pathway.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...

